Skip to main content
OpenTrials
Completed

NCT Number: NCT02604524

Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp

The biggest challenges for glycemic control during the day time involve meals and exercise variations, which are impacted by age, fitness level, duration, intensity and history of exercise. Meal variability has the benefit that meals are typically announced and quantified. Glucose control around exercise, on the other hand, is more complicated if the patient doesn't announce a change in activity level.

Completed

Looking for future studies?

Notify Me

Key information

Age range

10 year–25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Colorado, Denver, Barbara Davis Center, Aurora, Colorado, United States

Loading trial locations.

About this study

The object of this study is to evaluate the Closed-Loop Control (CLC) in an environment where muscle glycogen is systematically depleted, glucose uptake systematically increased, and meal sizes are naturally larger than normal: a week of camp at high altitude, with the concomitant variable of oxygen consumption that this environment involves; during the winter, that will expose and challenge the different components of the system during cold temperatures, and with twice daily practice of physical activity designed to deplete glycogen reserves such as skiing.

This proposal aims to demonstrate the superiority of the CLC, also known as Artificial Pancreas (AP), compared to the state-of-the art system available on the market: Sensor-augmented pump (SAP). This system has shown to diminish hypoglycemic events by setting the alarms on the continues glucose monitor (CGM) and taken action, such as performing self-monitoring blood glucose (SMBG) and treating if it is confirm to be low.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

To be eligible for the study, a subject must meet the following:

  • Criteria for documented hyperglycemia (at least 1 must be met):
  • Clinical diagnosis of type 1 diabetes (C-peptide levels and antibody determinations are not required)
  • The diagnosis of type 1 diabetes is based on the investigator's judgment
  • Criteria for requiring insulin at diagnosis (both criteria must be met):
  • Daily insulin therapy for ≥ 12 months
  • Insulin pump therapy for ≥ 3 months
  • Age 10 - 25 years
  • Avoidance of acetaminophen-containing medications (i.e. Tylenol) while wearing the continuous glucose monitor.
  • Willingness to wear a continuous glucose sensor and physiological monitor for the duration of the study
  • Female subjects who are sexually active must be on acceptable method of contraception (e.g. oral contraceptive pill, diaphragm, IUD)

Exclusion criteria

The presence of any of the following is an exclusion for the study:

  • Diabetic ketoacidosis in the past 6 months
  • Hypoglycemic seizure or loss of consciousness in the past 6 months
  • History of seizure disorder (except for hypoglycemic seizure)
  • History of any heart disease including coronary artery disease, heart failure, or arrhythmias
  • History of altitude sickness
  • Chronic pulmonary conditions that could impair oxygenation
  • Cystic fibrosis
  • Current use of oral glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study.
  • History of ongoing renal disease (other than microalbuminuria).
  • Subjects requiring intermediate or long-acting insulin (such as NPH, Detemir or Glargine).
  • Subjects requiring other anti-diabetic medications other than insulin (oral or injectable).
  • Pregnancy
  • Sexually active females who do not practice acceptable contraceptive methods to prevent pregnancy.
  • Presence of a febrile illness within 24 hours of start ski camp or acetaminophen use while wearing the CGM. The camp study subject will not participate in the trial if these conditions are met.
  • Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as:
  • Inpatient psychiatric treatment in the past 6 months
  • Uncontrolled adrenal insufficiency
  • Alcohol abuse

Treatment and study plan

Closed-loop control

Device

Subjects will use the CLC during 5 nights/6 days at a ski camp.

Other names: CLC

Sensor Augmented Pump Therapy

Other

Subjects using their personal pumps with study CGM.

Other names: SAP

Primary outcomes

  1. Time in range when using closed-loop compared with SAP.

    Time frame: 120-144 hours

Secondary outcomes

  1. Reduction of hypoglycemia episodes when using closed-loop

    Time frame: 120-144 hours

    assessed by the number of hypoglycemia treatments were needed for each group

Sponsors and collaborators

Lead sponsor

Daniel Chernavvsky, MD, CRC

Other

Collaborators

  • DexCom, Inc.
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Nov 13, 2015
Registry last updated
Sep 19, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.